These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30448598)

  • 81. [Efficacy of 48-week tenofovir disoproxil fumarate therapy in patients who were unresponsive to nucleoside-analogue treatments].
    Huang M; Li X; Wu Y; Tao L; Jie Y; Li X; Shi H; Lin G; Yang F; Ao Y; Pang Y; Zhang M; Chong Y
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):266-71. PubMed ID: 25173224
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.
    Yim HJ; Kim JH; Cho YK; Kweon YO; Cho HC; Hwang JS; Lee C; Koh MS; Baek YH; Park YM; Lee JH; Kim SU; Kang MK; Park NH; Lee JS; Chon YE; Cheon GJ; Chae HB; Sohn JH; Lim YS
    Drug Des Devel Ther; 2022; 16():3263-3274. PubMed ID: 36177347
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
    Batirel A; Guclu E; Arslan F; Kocak F; Karabay O; Ozer S; Turanli M; Mert A
    Int J Infect Dis; 2014 Nov; 28():153-9. PubMed ID: 25286184
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
    Hsu YC; Wei MT; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Nov; 11(11):999-1008. PubMed ID: 28965428
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B].
    Choi K; Lee HM; Jun BG; Lee SH; Kim HS; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Kim YD; Cheon GJ
    Korean J Gastroenterol; 2015 Jan; 65(1):35-42. PubMed ID: 25603852
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
    Liang X; Xie Q; Shang J; Tang H; Xu M; Meng Q; Zhang J; Gao P; Sheng J; Wang H; Jia J; Wang G; Wu S; Ping J; Hou J
    J Gastroenterol Hepatol; 2022 Mar; 37(3):471-479. PubMed ID: 34894002
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
    Liaw YF; Sheen IS; Lee CM; Akarca US; Papatheodoridis GV; Suet-Hing Wong F; Chang TT; Horban A; Wang C; Kwan P; Buti M; Prieto M; Berg T; Kitrinos K; Peschell K; Mondou E; Frederick D; Rousseau F; Schiff ER
    Hepatology; 2011 Jan; 53(1):62-72. PubMed ID: 21254162
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48.
    Liang RY; Xu JH; Si CW; Wang S; Shang J; Yu ZJ; Mao Q; Xie Q; Zhao W; Li J; Gao ZL; Wu SM; Tang H; Cheng J; Chen XY; Zhang WH; Wang H; Xu ZN; Wang L; Dai J; Yu YY
    Medicine (Baltimore); 2019 Aug; 98(33):e16778. PubMed ID: 31415381
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study.
    Zheng S; Liu L; Lu J; Zhang X; Shen H; Zhang H; Xue Y; Lin L
    Medicine (Baltimore); 2019 Oct; 98(42):e17590. PubMed ID: 31626130
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B.
    Song JE; Park JY
    Expert Opin Pharmacother; 2021 Dec; 22(18):2427-2433. PubMed ID: 34392744
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study.
    Janssen HLA; Lim YS; Lampertico P; Heo J; Chen CY; Fournier C; Tsang TYO; Bae H; Chen CH; Coffin CS; Ahn SH; Trinh H; Flaherty JF; Abramov F; Zhao Y; Liu Y; Lau A; German P; Chuang WL; Agarwal K; Gane E
    Lancet Gastroenterol Hepatol; 2024 Aug; 9(8):718-733. PubMed ID: 38901444
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan.
    Hsu CW; Chen SC; Wang PN; Wang HM; Chen YC; Yeh CT
    Hepatol Int; 2024 Apr; 18(2):449-460. PubMed ID: 38376651
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.
    Park JW; Kwak KM; Kim SE; Jang MK; Suk KT; Kim DJ; Park SH; Lee MS; Kim HS; Park CK
    BMC Gastroenterol; 2017 Mar; 17(1):39. PubMed ID: 28279168
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
    Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
    J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.
    Nam H; Han JW; Lee SK; Yang H; Lee HL; Sung PS; Song MJ; Kwon JH; Jang JW; Chang UI; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK; Yang JM; Kim HY
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1673-1683. PubMed ID: 38690711
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
    Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.
    Lee SH; Cheon GJ; Kim HS; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS; Jun BG; Don Kim Y; Jun DW; Sohn JH; Kim TY; Lee BS
    Antivir Ther; 2018; 23(3):219-227. PubMed ID: 28436380
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.
    Lee YB; Jung EU; Kim BH; Lee JH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Lee DH; Cho EJ; Yu SJ; Park SJ; Kim YJ; Park JW; Lee YJ; Kim CM; Yoon JH; Kim CY; Lee HS
    Antimicrob Agents Chemother; 2015 Feb; 59(2):972-8. PubMed ID: 25421484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.